In Chinese males with congenital hypogonadotropic hypogonadism, 70.2% of those treated with cyclical gonadotropins or a pulsatile gonadorelin pump, pooled, reached spermatogenesis within 3 years.
In plain wordsIn men with congenital hypogonadotropic hypogonadism, 70.2% treated with either of two therapies, a gonadorelin pump among them, reached sperm production within 3 years.
- Peptide
- Gonadorelin (GnRH, LHRH)
- Outcome
- IncreaseSpermatogenesis within 3 years
- Study
n: not reported in source
- Outcome group
- Sex hormones and fertility · Reproductive and sexual health
Measurements
- Reached spermatogenesis
- 70.2%
- CGT or PGP pooled, 3 years
Source sentences
Among the CHH males treated with CGT or PGP, 70.2% reached spermatogenesis within 3 years of treatment.
2 context sentences(design, population, supporting numbers)
Whole exome sequencing was performed for 73 Chinese CHH males from one academic center.
Patients self-selected one of the 4 treatments: pulsatile Gonadorelin pump (PGP), cyclical gonadotropins therapy (CGT), human menopausal gonadotropin monotherapy, or testosterone replacement treatment.
In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).